Genetically engineered bacterium for producing L-histidine as well as preparation method and application of genetically engineered bacterium
By overexpressing tauA gene and strongly expressing HisG mutants in genetically engineered strains, the L-histidine synthesis pathway was optimized, and the problem of low yield and conversion in the prior art was solved, and more efficient L-histidine was achieved Production has enhanced its industrial application potential.
Patent Information
- Application Number
- CN202411509687.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The yield and conversion rate of L-histidine in the prior art is low, limiting its industrial application in the fields of food, feed and medicine.
Optimize the synthesis pathway of L-histidine by overexpressing the tauA gene in genetically engineered strains and combining strong expression of the HisG mutant of ATP-transphosphorus ribosylase HisG and enhanced expression of the histidine operon gene. , improve product synthesis and efflux capabilities.
It significantly improves the yield and conversion rate of L-histidine, and enhances its potential in large-scale industrial production, which is specifically manifested as an increase in L-histidine concentration and conversion rate, providing a more efficient production solution.
Smart Images

Figure CN119020253A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of genetic engineering, and in particular to a genetic engineering bacterium for producing L-histidine, and a preparation method and application thereof. Background Art
[0002] L-histidine is widely used in food, feed, medicine and other fields, and has important economic and social value.
[0003] At present, there are three main methods for producing L-histidine: microbial fermentation, chemical synthesis, and enzyme catalysis. Among them, microbial fermentation has the advantages of a wide range of raw materials, relatively simple production process, relatively small impact on the environment, and high product purity, and has gradually become the mainstream method for L-histidine production.
[0004] Breeding efficient strains with the ability to produce L-histidine is the key to the industrial application of microbial fermentation. At present, there are two main methods for breeding L-histidine production strains: 1) Irrational mutagenesis screening: This method mainly uses physical or chemical methods to mutagenize wild-type chassis microorganisms, combined with L-histidine structural analog resistance screening methods, to breed mutagenized strains that have antagonistic effects on L-histidine. After multiple rounds of mutagenesis, excellent production strains with the ability to synthesize L-histidine are finally screened out. 2) Rational metabolic engineering transformation: This method mainly uses efficient gene editing technology to systematically metabolize the synthesis network of target metabolites in chassis microorganisms to maximize the redirection of carbon metabolic flux to the L-histidine synthesis pathway, mainly including removing the key enzyme feedback inhibition regulation mechanism caused by product synthesis, strengthening the metabolic flux of the synthesis pathway, blocking the degradation pathway of the synthesis product, and modifying the product transmembrane transport system. With the rapid development of genetic engineering technology, the method of rational metabolic engineering transformation to construct efficient L-histidine production strains has gradually replaced the mutagenesis screening breeding method and become the mainstream method for breeding efficient and stable L-histidine production strains.
[0005] Improving the L-histidine production performance of chassis microorganisms is the continuous goal of rational metabolic engineering breeding. In the process of systematic reconstruction of the chassis microbial metabolic network, the enhancement or reduction of the expression intensity of the target gene is a common strategy to improve the L-histidine production performance. For example, weakening the expression of one or several genes in the competitive pathway for L-histidine synthesis and genes involved in the redistribution of carbon and nitrogen flux can significantly promote the synthesis of L-histidine; in addition, increasing the expression of key enzymes in the product synthesis pathway, increasing the expression of product efflux membrane proteins, and increasing the expression of key enzymes in the product precursor synthesis pathway also has a significant effect on improving the production of L-histidine in chassis microorganisms.
[0006] The strain with the highest histidine fermentation level reported so far is E. coli WHY3-1 (CN111321102A), which is based on E. coli W3110 and is constructed by removing the feedback regulation of histidine synthesis, enhancing the histidine synthesis pathway, and promoting the extracellular secretion of histidine. It can produce 60-65g / L of histidine in a 5L fermenter for 40-50h, with an average production intensity of 1.0-1.5g / (L×h) and a conversion rate of 0.18-0.22g histidine / g glucose. However, there is still much room for improvement in its histidine production and conversion rate. Summary of the invention
[0007] In view of the problems of low L-histidine yield and low conversion rate in the prior art, the present invention provides a genetically engineered bacterium for producing L-histidine and a preparation method and application thereof. The genetically engineered bacterium of the present invention can greatly increase the yield of L-histidine, providing a new option for large-scale industrial production.
[0008] The specific scheme of the present invention is summarized as follows: The first aspect of the present invention provides a genetically engineered bacterium for producing L-histidine, wherein the genetically engineered bacterium integrates the tauA gene into the engineered strain by overexpression. In a specific embodiment of the present invention, the protein encoded by the tauA gene is shown by SEQ ID NO.2. The nucleotide sequence of the tauA gene is a nucleotide sequence encoding the SEQ ID NO.2 protein, and specifically, the tauA nucleotide sequence is selected from at least one of the nucleotide sequences currently disclosed in the database or the nucleotide sequences optimized according to actual needs. Preferably, the nucleotide sequence is as shown in SEQ ID NO.1.
[0009] Furthermore, the genetically engineered bacteria also include the following operations: integrating the gene hisG* encoding the ATP phosphoribosyltransferase HisG mutant of Corynebacterium glutamicum as shown in SEQ ID NO.3 and making it strongly expressed; also enhancing the expression of the Escherichia coli histidine operon genes hisD, hisB, hisC, hisH, hisA, hisF and hisI on the genome; and also integrating the overexpression of the tauA gene into the engineered strain.
[0010] In a specific embodiment of the present invention, the genetically engineered bacteria is selected from at least one of Escherichia coli, Corynebacterium glutamicum, and Serratia marcescens. Preferably, the genetically engineered bacteria is Escherichia coli. Further, the method of overexpressing the tauA gene is selected from at least one of the following: 1) by introducing and / or increasing the copy number of the tauA gene in the bacterial genome; 2) Modify the expression regulatory sequence of the tauA gene.
[0011] Furthermore, the method for increasing the copy number of tauA gene in 1) is selected from at least one of the following: A. Use gene editing to increase the copy number of the tauA gene in bacterial chromosomes; B. Increasing the copy number of the tauA gene by using an autonomously replicating plasmid. Preferably, the autonomously replicating plasmid is selected from at least one of pET28a, pTrc99a, and pSTV28.
[0012] The method 2) for modifying the expression regulatory sequence of the tauA gene is selected from at least one of the following: a. replacing the promoter with a strong promoter, preferably, the strong promoter is selected from at least one of PT7, Ptrc, Ptac, Plac; b. Modifying the ribosome binding site, preferably, the ribosome binding site is selected from at least one of RBS03, RBS09 and RBS10.
[0013] The second aspect of the present invention provides the use of the genetically engineered bacteria in the fermentation production of L-histidine. Specifically, the fermentation method in the application includes at least one of a shake flask culture method and a fermenter culture method.
[0014] In a specific embodiment of the present invention, the fermentation medium for shake flask culture comprises the following components: glucose 20-30 g / L, yeast extract 2-5 g / L, peptone 2-4 g / L, KH2PO4 1-3 g / L, MgSO4·7H2O 1-2 g / L, FeSO4·7H2O 5-20 mg / L, MnSO4·7H2O 5-20 mg / L, VB1, VB3, VB5, VB12, VH each 1-3 mg / L, and the rest is water, pH 7.0-7.2. The fermentation medium used for fermenter culture includes the following components: glucose 10-20g / L, yeast extract 5-10g / L, trypsin 4-8g / L, K2HPO4 3g / L, MgSO4·7H2O 1.5-4g / L, FeSO4·7H2O 20-30mg / L, MnSO4·H2O 20-30mg / L, VB1, VB3, VB5, VB12, VH each 2-5mg / L, and the rest is water, pH 7.0-7.2.
[0015] The method for fermentation culture includes at least one of a shake flask culture method and / or a fermenter culture method. Specifically, the shake flask culture method includes the following steps: An inoculum amount of 10-15% of the volume of the seed culture solution was inoculated into a 500 mL Erlenmeyer flask (final volume of 30 mL) filled with fermentation medium, and the flask was sealed and fermented. The flask was shaken at 35-40° C. and 200 r / min. The pH was maintained at 7.0-7.2 during the fermentation process. 60-70% (m / v) glucose solution was added to maintain the fermentation process.
[0016] In a specific embodiment of the present invention, the method for fermentation includes a shake flask culture method, comprising the following steps: shake flask culture: the genetically engineered bacteria are activated to prepare a seed solution, which is inoculated into a 500mL conical flask containing a fermentation medium at a rate of 10-15%, sealed with nine layers of gauze, and cultured at 37°C and 200r / min with shaking. During the fermentation process, ammonia water is added to maintain the pH at 7.0-7.2; 60% (m / v) glucose solution is added to maintain the fermentation.
[0017] The last aspect of the present invention provides a method for preparing the genetically engineered bacteria, the method comprising the step of overexpressing tauA. Specifically, further, the method of overexpressing the tauA gene is selected from at least one of the following: 1) by introducing and / or increasing the copy number of the tauA gene in the bacterial genome; 2) Modify the expression regulatory sequence of the tauA gene.
[0018] Furthermore, the method for increasing the copy number of tauA gene in 1) is selected from at least one of the following: A. Use gene editing to increase the copy number of the tauA gene in bacterial chromosomes; B. Increasing the copy number of the tauA gene by using an autonomously replicating plasmid. Preferably, the autonomously replicating plasmid is selected from at least one of pET28a, pTrc99a, and pSTV28.
[0019] The method 2) for modifying the expression regulatory sequence of the tauA gene is selected from at least one of the following: a. replacing the promoter with a strong promoter, preferably, the strong promoter is selected from at least one of PT7, Ptrc, Ptac, Plac; b. Modifying the ribosome binding site, preferably, the ribosome binding site is selected from at least one of RBS03, RBS09 and RBS10.
[0020] The beneficial effects of the present invention include but are not limited to: Compared with the corresponding E. coli WHY2-3, the tauA gene of the strain is overexpressed, wherein the protein sequence encoded by the tauA gene is shown in SEQ ID NO. 2. Under the same shake flask fermentation culture conditions, compared with the E. coli WHY2-3 strain, the L-histidine concentration is increased from 2.67 g / L to 3.11 g / L, an increase of 16.5%, and the intracellular L-histidine content is reduced from 3.56 mg / DCW to 2.91 mg / DCW, a decrease of 18.2%; under the same fermentation tank fermentation culture conditions, compared with the E. coli WHY2-3 strain, the L-histidine yield is increased from 54.6 g / L to 67.2 g / L, the sugar-acid conversion rate is increased from 20.3% to 26.9%, and the L-histidine yield and conversion rate are increased by 23.1% and 32.5%, respectively, providing a new option for the large-scale industrial production of L-histidine. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings: Figure 1 : is a schematic diagram of the electrophoresis results of ycgH::tauA gene editing in an embodiment of the present invention, wherein M: 1kb DNA marker; 1: upstream homology arm; 2: tauA gene fragment; 3: downstream homology arm; 4: overlapping fragment; 5: original bacteria control; 6: positive bacteria identification fragment. DETAILED DESCRIPTION
[0022] In a first aspect, the present invention provides a genetically engineered bacterium for producing L-histidine, specifically, it belongs to Escherichia coli, and more specifically, the Escherichia coli is a strain E. coli WHY2-3 modified in a manner of overexpressing the tauA gene.
[0023] According to the first aspect of the present invention, the Escherichia coli is a strain E. coli WHY2-3 modified by overexpressing the tauA gene, so that compared with the unmodified Escherichia coli, the expression level of the tauA gene is increased, or the total activity of the tauA gene expression product, such as a taurine transporter, is increased, for example, by 150% or more, 200% or more, 300% or more.
[0024] According to the first aspect of the present invention, the strain E. coli WHY2-3 (described in detail in paragraphs
[0033] to
[0095] of the specification of Chinese patent CN111321102A) is a strain of Escherichia coli W3110 in which the nucleotide sequence of the Corynebacterium glutamicum ATP phosphoribosyltransferase HisG mutant encoding gene hisG* as shown in SEQ ID NO.3 is integrated into the genome of Escherichia coli W3110 and strongly expressed to enhance the activity of the key enzyme HisG for histidine synthesis; the expression of seven genes of the Escherichia coli histidine operon hisD, hisB, hisC, hisH, hisA, hisF and hisI is also enhanced on the genome, thereby enhancing the terminal synthesis pathway of histidine, and finally obtaining E. coli WHY2-3.
[0025] According to the first aspect of the present invention, the tauA gene can be overexpressed by introducing and / or increasing the copy number of the tauA gene in the bacterial genome (for example, increasing the copy number of the tauA gene through autonomously replicating plasmids such as pET28a, pTrc99a, pSTV28, or increasing the copy number of the tauA gene in the bacterial chromosome), or modifying the expression regulatory sequence of the tauA gene (for example, a promoter, a ribosome binding site, etc.), or a combination of the above methods.
[0026] In a second aspect, the present invention provides a method for producing L-histidine using the genetically engineered bacteria as described above, comprising: culturing the genetically engineered bacteria in a culture medium to produce L-histidine; and collecting the L-histidine from the genetically engineered bacteria and / or the culture medium.
[0027] The present invention is described below by specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood as illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material composition and dosage in these embodiments, without departing from the essence and scope of the present invention, also belong to the protection scope of the present invention.
[0028] The percentage sign "%" in the following examples, unless otherwise defined in the art or otherwise specified, refers to volume percentage; the percentage of a solution "% (m / v)" refers to the number of grams of a solute contained in 100 mL of the solution.
[0029] Example 1: Construction of genetically engineered strain HIS-tauA modified by overexpressing tauA gene 1 Methods of gene editing Unless otherwise specified, the gene editing method used in the embodiment of the present invention is carried out with reference to the literature (Li Y, Lin Z, Huang C, et al. Metabolic engineering of Escherichia coli using CRISPR-Cas9meditated genome editing. Metabolic engineering, 2015, 31: 13-21.). Among them, pREDCas9 carries the elimination system of the gRNA expression plasmid pGRB, the Red recombination system of λ phage and the Cas9 protein expression system, spectinomycin resistance (working concentration: 100 mg / L), and is cultured at 32°C; pGRB uses pUC18 as the skeleton, including the promoter J23100, the gRNA-Cas9 binding region sequence and the terminator sequence, ampicillin resistance (working concentration: 100 mg / L), and is cultured at 37°C. The specific steps of the method are as follows: 1.1 Construction of pGRB plasmid The purpose of constructing the plasmid pGRB is to transcribe the corresponding gRNA, thereby forming a complex with the Cas9 protein, and recognize the target gene target site through base pairing and PAM to achieve the target DNA double-strand break. The pGRB plasmid is constructed by recombination of a DNA fragment containing the target sequence with a linearized vector fragment. 1.1.1 Target sequence design The target sequence (PAM: 5'-NGG-3') was designed using CRISPR RGEN Tools.
[0030] 1.1.2 Preparation of DNA fragments containing target sequences Design primers: 5'-linearized vector end sequence (15 bp)-restriction site-target sequence (excluding PAM sequence)-linearized vector end sequence (15 bp)-3' and its reverse complementary primer, and prepare DNA fragments containing target sequences by annealing single-stranded DNA. Reaction conditions: pre-denaturation at 95°C, 5 min; annealing at 30-50°C, 1 min. The annealing system is shown in Table 1.
[0031] Table 1 Annealing system Reaction system Volume (20 μL) Primer (10 μmol / L) 10μL Reverse complementary primer (10 μmol / L) 10μL 1.1.3 Preparation of linear vector The vector was linearized by inverse PCR amplification.
[0032] 1.1.4 Recombination reaction All recombinant enzymes used were from the ClonExpress II One Step Cloning Kit series, and the recombinant conditions were 37°C, 30 min. The recombinant system is shown in Table 2.
[0033] Table 2 Recombination reaction system Reaction system Volume (20 μL) 5×CEⅡ Buffer 4μL Linearized cloning vector 1μL Insert cloning vector 1μL Exnase ®Ⅱ 2μL <![CDATA[ddH2O]]> 12μL 1.1.5 Plasmid transformation Take 10μL of the reaction solution and add it to 100mL of DH5α competent cells. Mix gently and place on ice for 20min. Heat shock at 42℃ for 45-90s. Place on ice for 2-3min. Add 900μL of SOC and resuscitate at 37℃ for 1h. Centrifuge at 8000rpm for 2min, discard part of the supernatant, and keep about 200μL to resuspend the cells and apply them to a plate containing 100mg / L ampicillin. Invert the plate and culture at 37℃ overnight. After a single colony grows on the plate, identify it by colony PCR and select the positive recombinants.
[0034] 1.1.6 Clone identification The PCR-positive colonies were inoculated into LB medium containing 100 mg / L ampicillin and cultured overnight to maintain the bacteria. The plasmids were extracted and identified by enzyme digestion.
[0035] 1.2 Preparation of recombinant DNA fragments The recombinant fragment used for promoter replacement consists of the upstream and downstream homology arms of the tauA gene (upstream homology arm-downstream homology arm). Using the primer design software primer5, the upstream and downstream sequences of the tauA gene were used as templates to design upstream and downstream homology arm primers (amplification length of about 400-600bp). After the upstream and downstream homology arms and the target gene fragment were amplified by PCR, the recombinant fragment was prepared by overlapping PCR. The PCR amplification system is shown in Table 3.
[0036] Table 3 PCR amplification system Components Volume (50 μL) DNA template 1μL Upstream primer (10 μmol / L) 1μL Downstream primer (10 μmol / L) 1μL dNTP mixture (10mmol / L) 4μL 5×Buffer 10μL HS enzyme 0.5μL <![CDATA[ddH2O]]> 32.5μL The overlapping PCR system is shown in Table 4.
[0037] Table 4 Overlap PCR system Components Volume (50 μL) template 1μL Upstream primer of upstream homology arm (10 μmol / L) 1μL Downstream homology arm downstream primer (10μmol / L) 1μL dNTP mixture (10mmol / L) 4μL 5×Buffer 10μL HS enzyme 0.5μL <![CDATA[ddH2O]]> 32.5μL Note: The template consists of equimolar amounts of the amplified fragments of the upstream and downstream homology arms and the target gene, and the total amount does not exceed 10 ng.
[0038] PCR reaction conditions (Bao Bio PrimeSTAR HS enzyme): pre-denaturation (95°C) for 5 min; then 30 cycles: denaturation (98°C) for 10 s, annealing ((Tm-3 / 5)°C) for 15 s, extension at 72°C (this enzyme activity extends about 1 kb per 1 min); continue extension at 72°C for 10 min; maintain (4°C).
[0039] 1.3 Transformation of plasmids and recombinant DNA fragments 1.3.1 Transformation with pREDCas9 The pREDCas9 plasmid was electroporated into the electroporation competent state of the starting strain by electroporation. After the bacteria were revived and cultured, they were spread on LB plates containing spectinomycin and cultured overnight at 32°C. Single colonies grown on the resistant plates were subjected to colony PCR using identification primers to screen positive recombinants.
[0040] 1.3.2 Preparation of electroporation competent cells of target strains containing pREDCas9 When the cells were cultured at 32°C until OD 600 = 0.1-0.2, 0.1 M IPTG was added (to a final concentration of 0.1 mM), and the cells were cultured until OD 600 = 0.6-0.7 for competent state preparation. The purpose of adding IPTG is to induce the expression of the recombinase on the pREDCas9 plasmid. The culture medium and preparation process required for competent state preparation refer to the conventional standard operation.
[0041] 1.3.3 Transformation of pGRB and recombinant DNA fragments pGRB and donor DNA fragments were electro-transformed into electro-competent cells containing pREDCas9 at the same time. The revived bacteria after electro-transformation were spread on LB plates containing ampicillin and spectinomycin and cultured at 32°C overnight. Colony PCR verification was performed using specially designed identification primers to screen positive recombinants and preserve the bacteria.
[0042] 1.4 Elimination of plasmid 1.4.1 Elimination of pGRB The positive recombinants were cultured overnight in LB medium containing 0.2% arabinose, and then appropriately diluted and spread on LB plates containing spectinomycin resistance, and cultured overnight at 32°C. For LB plates containing ampicillin and spectinomycin resistance, single colonies that did not grow on the ampicillin plate but grew on the spectinomycin resistance plate were selected for preservation.
[0043] 1.4.2 Elimination of pREDCas9 plasmid Transfer the positive recombinant to LB liquid medium without resistance, culture at 42℃ overnight, dilute appropriately and spread on LB plate without resistance, culture at 37℃ overnight. For LB plates containing spectinomycin resistance and LB plates without resistance, select single colonies that do not grow on spectinomycin resistance plates but grow on plates without resistance. 2. Primers used in strain construction are shown in Table 5.
[0044] Table 5 Primers used in strain construction
[0045] 3 Construction of ycgH::tauA gene editing strain Using the Escherichia coli genome as a template, upstream homology arm primers (UP-ycgH-S, UP-ycgH-A) and downstream homology arm primers (DN-ycgH-S, DN-ycgH-A) were designed according to the upstream and downstream sequences of its ycgH gene (NCBI GeneID: 2847703); according to the upstream and downstream sequences of the tauA gene (NCBI GeneID: 945030, the sequence is shown in SEQ ID NO.1), the primers tauA-S and tauA-A required for amplifying the tauA gene were designed. The above fragments were fused by overlapping PCR to obtain ycgH::tauA (upstream homology arm-downstream homology arm). Construction of pGRB-ycgH: The DNA fragment containing the target sequence was prepared by annealing primers gRNA-ycgH-S and gRNA-ycgH-A. Prepare competent cells of E. coli WHY2-3, and operate according to the methods shown in 1.3 and 1.4 above to construct the genetically engineered strain HIS-tauA modified by overexpressing the tauA gene. The electrophoresis diagram of the construction of the ycgH::tauA fragment and the PCR verification of the positive strain is attached. Figure 1 Among them, the length of the upstream homology arm should be 517bp, the length of the tauA fragment should be 1323bp, the length of the downstream homology arm should be 556bp, and the total length of the overlapping fragments should be 2396bp. During PCR verification, the length of the PCR amplification fragment of positive bacteria should be 2396bp, and the length of the PCR amplification fragment of the original bacteria should be 1416bp.
[0046] Example 2: Production of L-histidine by shake flask fermentation using Escherichia coli HIS-tauA with overexpressed tauA gene E. coli HIS-tauA is modified by overexpressing the tauA gene on the basis of E. coli WHY2-3. The E. coli WHY2-3 strain (described in detail in the specification of Chinese patent CN111321102A
[0033] to
[0095] ) is a strain of E. coli W3110, in which the nucleotide sequence of the glutamicum ATP phosphoribosyltransferase HisG mutant encoding gene hisG* as shown in SEQ ID NO.3 is integrated into the genome of E. coli W3110 and strongly expressed to enhance the activity of the key enzyme HisG in histidine synthesis; the expression of seven genes of the E. coli histidine operon hisD, hisB, hisC, hisH, hisA, hisF and hisI is also enhanced on the genome, thereby enhancing the terminal synthesis pathway of histidine, and finally obtaining E. coli WHY2-3.
[0047] Shake flask fermentation method: The same culture medium and culture method were used to culture Escherichia coli HIS-tauA and control Escherichia coli E. coli WHY2-3 in shake flasks to produce L-histidine.
[0048] The composition of the culture medium: glucose 20 g / L, yeast extract 3 g / L, peptone 2 g / L, K2HPO4 6 g / L, MgSO4·7H2O 1 g / L, FeSO4·7H2O 20 mg / L, MnSO4·7H2O 20 mg / L, V B1 、V B3 、V B5 、V B12 、V H 1 mg / L each, the rest is water, pH 7.0-7.2.
[0049] Shake flask culture steps: inoculate 10% of the volume of the seed culture solution into a 500mL Erlenmeyer flask containing fermentation medium (final volume is 30mL), seal with nine layers of gauze, and culture at 37°C, 200r / min with shaking. During the fermentation process, the pH is maintained at 7.0-7.2 by adding ammonia water; and 60% (m / v) glucose solution is added to maintain the fermentation.
[0050] After 24 hours of fermentation in a shake flask, 1 mL of the fermentation broth was taken from each culture to remove the bacteria at 13,000 rpm to obtain the fermentation supernatant. The L-histidine concentration in the fermentation supernatant was detected by high performance liquid chromatography (as shown in Table 6).
[0051] Determination of intracellular histidine content: After the shake flask fermentation, 30 mL of fermentation liquid was centrifuged and the supernatant was discarded. The bacterial precipitate was resuspended with physiological saline and centrifuged to wash away the interference of extracellular components. After repeating twice, the bacterial cells were obtained and the dry weight of the bacteria was recorded; the washed bacterial cells were fixed to 30 mL with physiological saline and the cells were broken by high-pressure homogenization. The initial crushing pressure of the high-pressure homogenization method was 0 N. When the pressure was gradually increased to 200 N, it was maintained for a short period of time, and then the crushing pressure was gradually increased to 800 N for 5 min to complete the cell crushing. The crushing liquid was collected, and the supernatant was taken after high-speed centrifugation to analyze the intracellular L-histidine content by high-performance liquid chromatography (as shown in Table 6).
[0052] Table 6 Shake flask fermentation results of HIS-tauA strain
[0053] The results in Table 6 show that overexpression of the tauA gene did not significantly affect the growth of the engineered strain; at the same time, under the condition of consuming the same amount of substrate glucose, the L-histidine production of HIS-tauA increased from 2.67 g / L to 3.11 g / L compared with the starting strain WHY2-3, and the L-histidine yield and conversion rate increased by 16.5%, and the intracellular L-histidine content decreased from 3.56 mg / DCW to 2.91 mg / DCW, a decrease of 18.2%. The above experimental results show that the production of L-histidine by fermentation of genetically engineered bacteria modified by overexpressing the tauA gene significantly improves the L-histidine production performance, indicating that the modified strain has a stronger L-histidine production capacity.
[0054] (2) Fermentation in a 5L fermenter The same culture medium and culture method were used to ferment Escherichia coli HIS-tauA and control Escherichia coli E. coli WHY2-3 in a 5L fermenter to produce L-histidine.
[0055] Slant activation: streak the glycerol-preserved strains onto the slant medium in a test tube and culture at 37°C for 12 h; then streak the slant-preserved strains onto the slant medium in an eggplant-shaped flask and culture at 37°C for 14 h; Seed culture: Take one activated fresh eggplant-shaped flask slope, wash it with 150 mL of sterile water, and inoculate it into the fermenter under flame protection. The temperature is controlled at 37°C, and ammonia water is automatically added to control the pH at 7.0. The initial aeration rate is 2 L / min, and the initial stirring speed is 200 rpm. During the culture process, the DO value is maintained between 20-30%. The seeds are cultured until OD 600 About 15; Fermentation tank culture steps: the fermentation tank seeds are inoculated with 15% seed liquid (discharge 450mL, and pour the sterilized fermentation medium under flame protection), the temperature is controlled at 35°C, ammonia water (or 20% sulfuric acid) is automatically added to control the pH at 7.0, the initial ventilation rate is 2L / min, the ventilation ratio is 0.667vvm, the initial stirring speed is 400 rpm, the dissolved oxygen is controlled at 20-30% by adjusting the speed and air volume, and foam is manually added to remove foam. During the fermentation process, 80% glucose solution is added to ensure sufficient sugar supply and the sugar concentration is not higher than 5g / L; The composition of the slant medium is: glucose 1g / L, peptone 10g / L, beef extract 10g / L, yeast powder 5g / L, NaCl 2.5g / L, agar 25g / L, and the rest is water, pH 7.0-7.2; The composition of the seed culture medium is: glucose 10g / L, yeast extract 5g / L, peptone 5g / L, KH2PO4 5g / L, MgSO4·7H2O 2g / L, FeSO4·7H2O 10mg / L, MnSO4·H2O10mg / L, VB1 2mg / L, VH 1mg / L, 2 drops of defoaming agent, and the rest is water, pH 7.0-7.2; The fermentation medium consists of 10 g / L glucose, 5 g / L yeast extract, 4 g / L tryptone, 3 g / L K2HPO4, 1.5 g / L MgSO4·7H2O, 20 mg / L FeSO4·7H2O, 20 mg / L MnSO4·H2O, 2 mg / L each of VB1, VB3, VB5, VB12 and VH, and the rest is water, pH 7.0 - 7.2.
[0056] The fermentation results of the two strains in the 5L tank are shown in Table 7.
[0057] Table 7 Fermentation results of HIS-tauA strain fermentation tank culture
[0058] The results in Table 7 show that overexpression of the tauA gene did not significantly affect the growth of the engineered strain; however, under the same fermentation conditions in a 5L fermenter, the L-histidine production of HIS-tauA increased from 54.6 g / L to 67.2 g / L, the sugar-acid conversion rate increased from 20.3% to 26.9%, and the L-histidine yield and conversion rate increased by 23.1% and 32.5%, respectively, compared with the starting strain WHY2-3. The above experimental results show that genetically engineered bacteria modified by overexpressing the tauA gene have better potential for large-scale production of L-histidine, and the fermentation index of HIS-tauA in a 5L tank is the highest level reported so far.
[0059] The above description is only an embodiment of the present invention. The protection scope of the present invention is not limited by these specific embodiments, but is determined by the claims of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent substitution, improvement, etc. made within the technical ideas and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A genetically engineered bacterium for producing L-histidine, It is characterized in that The genetically engineered bacteria integrates the tauA gene into the engineered strain by overexpression.
2. The genetically engineered bacterium according to claim 1, It is characterized in that The protein encoded by the tauA gene is shown by SEQ ID NO.
2.
3. The genetically engineered bacterium according to claim 1, It is characterized in that The nucleotide sequence of the tauA gene is a nucleotide sequence encoding the protein shown in SEQ ID NO.
2.
4. The genetically engineered bacteria according to claim 1, It is characterized in that The genetically engineered bacteria also include the following operations: integrating the nucleotide sequence of the Corynebacterium glutamicum ATP phosphoribosyltransferase HisG mutant encoding gene hisG* as shown in SEQ ID NO.3 and making it strongly expressed; and also enhancing the expression of histidine operon genes hisD, hisB, hisC, hisH, hisA, hisF and hisI on the genome.
5. The genetically engineered bacterium according to claim 1, It is characterized in that The genetically engineered bacteria is selected from at least one of Escherichia coli, Corynebacterium glutamicum and Serratia.
6. The genetically engineered bacterium according to claim 1, It is characterized in that The method of overexpressing the tauA gene is selected from at least one of the following: 1) by introducing and / or increasing the copy number of the tauA gene in the bacterial genome; 2) Modify the expression regulatory sequence of the tauA gene.
7. The genetically engineered bacterium according to claim 6, It is characterized in that The method for increasing the copy number of the tauA gene in 1) is selected from at least one of the following: A. Use gene editing to increase the copy number of the tauA gene in bacterial chromosomes; B. Increasing the copy number of tauA gene by autonomously replicating plasmid.
8. Use of the genetically engineered bacteria according to any one of claims 1 to 7 in the fermentation production of L-histidine.
9. The use according to claim 8, It is characterized in that The fermentation method in the application comprises at least one of a shake flask fermentation method and a fermenter fermentation method.
10. A method for preparing the genetically engineered bacteria according to any one of claims 1 to 7, It is characterized in that The method comprises the step of overexpressing tauA.
Citation Information
Patent Citations
Genetically engineered bacterium for producing L-histidine and application of genetically engineered bacterium
CN111321102A
Industrially useful microorganism
CN101115832A
High-yield L-histidine genetically engineered bacterium strain, constructing method and application thereof
CN110184230A
Unnatural base pair compositions and methods of use
CN112105627A
Method for producing L-histidine using bacteria of enterobacteriaceae family
EP1510570A2
